Skip to content

Paradigm Biopharmaceuticals finished the week on a high with progression for its PPS drug.

ASX closed lower; Computershare hit a 52-week high; Paradigm Biopharmaceuticals rallied on trial approval

The ASX200 closed 0.37% lower on Friday at 7342.60 points.

Computershare hit a 52-week high as founder resigned from the board.

Paradigm Biopharmaceuticals rallied on approval for phase 3 clinical trial.

The Australian market closed 0.37% lower at 7342.60 on Friday as the gold miners led losses on the ASX with Ramelius Resources posting the greatest loss of 5.73%. The turbulent start to the week meant the ASX posted a 0.83% loss for the week.

The tech sector overturned a morning rally to close lower today as Wisetech Global fell 2.58%, Xero lost 2.52% and Appen closed the session 2.03% lower.

Bitcoin is trading 1.21% higher over the last 24-hours at US$44,363.33 at 4:30pm AEST.

Financial administration company Computershare soared to a 52-week high share price of $17.95 during today’s session following the company announcing that founder, Chris Morris, will leave the board on November 11. Chris Morris will be replaced on the board by John Nendick, a ‘senior financial executive who is an expert in new business models, global financial, account and audit matters’ and other expertise.

Making headlines, Australian-based Paradigm Biopharma jumped 2.4% today after providing an update on its upcoming clinical trial. Paradigm announced that it has received an Australian ethics approval for its pivotal phase 3 clinical trial in participants with knee osteoarthritis pain. The study will trial Paradigm’s PPS and a placebo given to patients with Osteoarthritis Pain.

And popular digital pet game from 2005, Neopets, is revamping through the launch of its first NFT collection, the Neopets Metaverse collection.

See more stories like this

    Your Cart
    Your cart is emptyReturn to Shop
      Apply Coupon